All In Biotech

Drug Trial Radar · NCT00431093

Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)

A Multicenter, Randomized, Double-Blind, Double Dummy, Group-Comparative Trial to Compare the Effects of Livial® and Activelle ® on the Vaginal Bleeding Pattern, Vasomotor Complaints, Vaginal Atrophy, QoL and Sexual Function

Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

570

Actual

Start

Nov 2002

Primary completion

Mar 2005

Study completion Mar 2005

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Feb 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 45 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present trial is undertaken to compare the effects of Tibolone with a low-dose HRT regimen.

Conditions

  • Menopause

Interventions

  • tiboloneDrug

    uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).

  • low-dose estradiol/noresteroneDrug

    Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets. Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For the bleeding evaluation, subject will be given a diary card to record the days on which no bleeding, vaginal spotting or bleeding occursTime frame: starting from baseline and during the whole trial period.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.